

Robert P Frantz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9157924/robert-p-frantz-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150 papers	9,195 citations	45 h-index	94 g-index
160 ext. papers	11,174 ext. citations	4.7 avg, IF	5.68 L-index

#	Paper	IF	Citations
150	Definitions and diagnosis of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, D42-50	15.1	1163
149	Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). <i>Circulation</i> , 2010 , 122, 164-72	16.7	1079
148	The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. <i>Chest</i> , 2012 , 141, 354-362	5.3	329
147	Risk stratification and medical therapy of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	316
146	Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 1380-6	15.1	274
145	Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2013 , 6, 711-21	3.9	256
144	Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. <i>Chest</i> , 2011 , 139, 1299-1309	5.3	254
143	Portopulmonary hypertension: Results from a 10-year screening algorithm. <i>Hepatology</i> , 2006 , 44, 1502-10	11.2	246
142	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. <i>Chest</i> , 2012 , 142, 1383-1390	5.3	242
141	Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. <i>Hepatology</i> , 1999 , 30, 641-8	11.2	220
140	Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. <i>Chest</i> , 2019 , 156, 323-337	5.3	201
139	Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). <i>BMJ, The</i> , 2016 , 353, i1246	5.9	196
138	Readmissions after implantation of axial flow left ventricular assist device. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 153-63	15.1	191
137	Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. <i>Circulation</i> , 2009 , 120, 2170-6	16.7	171
136	World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 212-23	5.8	165
135	Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. <i>Liver Transplantation</i> , 2000 , 6, 453-8	4.5	144
134	Changes in renal function after implantation of continuous-flow left ventricular assist devices. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 26-36	15.1	139

133	Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. <i>Circulation</i> , 2018 , 137, 1796-1810	16.7	130
132	Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. <i>Circulation</i> , 2007 , 116, 2726-33	16.7	129
131	Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. <i>Circulation</i> , 2003 , 108, 143-9	16.7	127
130	Role of serial quantitative assessment of right ventricular function by strain in pulmonary arterial hypertension. <i>American Journal of Cardiology</i> , 2013 , 111, 143-8	3	113
129	Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2009 , 28, 320-7	5.8	111
128	Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. <i>Chest</i> , 2011 , 139, 1285-1293	5.3	100
127	Combined heart and liver transplantation: a single-center experience. <i>Transplantation</i> , 2009 , 88, 219-25	1.8	98
126	Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2008 , 27, 823-9	5.8	96
125	Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 1207-13	6.4	91
124	Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. <i>Circulation</i> , 2012 , 125, 708-20	16.7	89
123	Impaired left ventricular mechanics in pulmonary arterial hypertension: identification of a cohort at high risk. <i>Circulation: Heart Failure</i> , 2013 , 6, 748-55	7.6	83
122	Echocardiographic variables after left ventricular assist device implantation associated with adverse outcome. <i>Circulation: Cardiovascular Imaging</i> , 2011 , 4, 648-61	3.9	81
121	Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. <i>Journal of Heart and Lung Transplantation</i> , 2005 , 24, 2129-36	5.8	75
120	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 1366-75	5.8	72
119	Relation of tissue displacement and strain to invasively determined right ventricular stroke volume. <i>American Journal of Cardiology</i> , 2005 , 96, 1173-8	3	69
118	Reference Values for Right Ventricular Strain in Patients without Cardiopulmonary Disease: A Prospective Evaluation and Meta-Analysis. <i>Echocardiography</i> , 2015 , 32, 787-96	1.5	68
117	Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage. <i>Chest</i> , 2013 , 144, 1530-1538	5.3	60
116	Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. <i>Transplantation</i> , 2007 , 84, 467-74	1.8	58

115	Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST). <i>Circulation</i> , 2003 , 108, 2336-41	16.7	58
114	PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics. <i>Circulation Research</i> , 2017 , 121, 1136-1139	15.7	58
113	Increase in total plasma homocysteine concentration after cardiac transplantation. <i>Mayo Clinic Proceedings</i> , 1995 , 70, 125-31	6.4	56
112	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 227-238	35.1	55
111	Clinical predictors of exercise capacity 1 year after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2003 , 22, 16-27	5.8	52
110	Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 1102-8	5.8	50
109	Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: a three-dimensional volumetric intravascular ultrasound study. <i>Transplantation</i> , 2013 , 95, 389-96	1.8	50
108	Causes of breathing inefficiency during exercise in heart failure. <i>Journal of Cardiac Failure</i> , 2010 , 16, 835-42	3.3	49
107	Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. <i>American Heart Journal</i> , 2005 , 149, 541-7	4.9	49
106	Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 636-650	15.1	48
105	Usefulness of the six-minute walk test after continuous axial flow left ventricular device implantation to predict survival. <i>American Journal of Cardiology</i> , 2012 , 110, 1322-8	3	45
104	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. <i>World Journal of Transplantation</i> , 2016 , 6, 380-8	2.3	44
103	Effects of acute changes in pulmonary wedge pressure on periodic breathing at rest in heart failure patients. <i>American Heart Journal</i> , 2007 , 153, 104.e1-7	4.9	43
102	Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2007 , 26, 826-33	5.8	42
101	Combined heart and kidney transplantation provides an excellent survival and decreases risk of cardiac cellular rejection and coronary allograft vasculopathy. <i>Transplantation Proceedings</i> , 2011 , 43, 1871-6	1.1	40
100	Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft. <i>Transplantation</i> , 2008 , 86, 1395-400	1.8	39
99	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1661-1670	10.2	38
98	Partial normalization of the heart rate response to exercise after cardiac transplantation: frequency and relationship to exercise capacity. <i>Mayo Clinic Proceedings</i> , 2002 , 77, 1295-300	6.4	34

97	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial. <i>Chest</i> , 2016 , 150, 27-34	5.3	34
96	Survival in pulmonary arterial hypertension patients awaiting lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2013 , 32, 1179-86	5.8	33
95	The usefulness of submaximal exercise gas exchange to define pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 1133-42	5.8	33
94	Right ventricular pressure waveform and wave reflection analysis in patients with pulmonary arterial hypertension. <i>Chest</i> , 2007 , 132, 37-43	5.3	33
93	Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional survey. <i>Pulmonary Circulation</i> , 2014 , 4, 504-10	2.7	31
92	Combined heart and liver transplant attenuates cardiac allograft vasculopathy compared with isolated heart transplantation. <i>Transplantation</i> , 2013 , 95, 859-65	1.8	31
91	Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2008 , 27, 780-8	5.8	30
90	Imatinib in pulmonary arterial hypertension: c-Kit inhibition. <i>Pulmonary Circulation</i> , 2014 , 4, 452-5	2.7	29
89	Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality. <i>American Journal of Transplantation</i> , 2009 , 9, 132-9	8.7	29
88	Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. <i>European Journal of Applied Physiology</i> , 2008 , 103, 421-30	3.4	29
87	The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. <i>Journal of Cardiac Failure</i> , 2008 , 14, 267-75	3.3	28
86	Repeat length polymorphism of the serotonin transporter gene influences pulmonary artery pressure in heart failure. <i>American Heart Journal</i> , 2007 , 153, 426-32	4.9	28
85	Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. <i>Chest</i> , 2015 , 147, 484-494	5.3	27
84	Unraveling the RV Ejection Doppler Envelope: Insight Into Pulmonary Artery Hemodynamics and Disease Severity. <i>JACC: Cardiovascular Imaging</i> , 2017 , 10, 1268-1277	8.4	24
83	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. <i>Chest</i> , 2018 , 154, 126-135	5.3	23
82	Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. <i>Chest</i> , 2018 , 154, 848-861	5.3	23
81	Right ventricular function with hypoxic exercise: effects of sildenafil. <i>European Journal of Applied Physiology</i> , 2007 , 102, 87-95	3.4	22
80	Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019 , 3, 311-318	3.1	20

79	Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. <i>Chest</i> , 2016 , 149, 362-371	5.3	20
78	Heart transplantation for radiation-associated end-stage heart failure. <i>Transplant International</i> , 2000 , 13, 162-165	3	19
77	Usefulness of High-Density Lipoprotein Cholesterol to Predict Survival in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2016 , 118, 292-7	3	18
76	Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. <i>Journal of Heart and Lung Transplantation</i> , 2012 , 31, 811-6	5.8	16
75	The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. <i>European Journal of Applied Physiology</i> , 2009 , 106, 509-15	3.4	16
74	Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST). <i>Journal of Cardiac Failure</i> , 2007 , 13, 437-44	3.3	16
73	Recipient selection and management before cardiac transplantation. <i>American Journal of the Medical Sciences</i> , 1997 , 314, 139-52	2.2	16
72	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 696-705	5.8	16
71	Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure. <i>Chest</i> , 2017 , 152, 1128-1134	5.3	15
70	B-type natriuretic peptide levels and continuous-flow left ventricular assist devices. <i>ASAIO Journal</i> , 2010 , 56, 527-31	3.6	15
69	Submaximal Exercise Pulmonary Gas Exchange in Left Heart Disease Patients With Different Forms of Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2015 , 21, 647-55	3.3	14
68	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020 , 157, 955-965	5.3	14
67	The prognostic significance of tricuspid valve regurgitation in pulmonary arterial hypertension. <i>Clinical Respiratory Journal</i> , 2018 , 12, 1572-1580	1.7	13
66	A pulmonary hypertension gas exchange severity (PH-GXS) score to assist with the assessment and monitoring of pulmonary arterial hypertension. <i>American Journal of Cardiology</i> , 2012 , 109, 1066-72	3	13
65	TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 658-65	1.9	13
64	Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. <i>Transplantation</i> , 2008 , 85, 963-8 ^{1.8}		13
63	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 1472-1487	10.2	13
62	Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation. <i>Journal of the American Heart Association</i> , 2019 , 8, e012073	6	12

61	A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost. <i>Pulmonary Circulation</i> , 2013 , 3, 381-8	2.7	12
60	Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension. <i>Pharmacotherapy</i> , 2017 , 37, e76-e81	5.8	11
59	Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1049-60	7	11
58	Techniques of immunosuppression after cardiac transplantation. <i>Mayo Clinic Proceedings</i> , 1992 , 67, 586-854	8.4	11
57	Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: a randomized trial. <i>Transplantation</i> , 1997 , 63, 1607-10	1.8	11
56	Long-term results of the DeLLiVeRy for Pulmonary Arterial Hypertension trial. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894019878615	2.7	11
55	Early Gains in Renal Function Following Implantation of HeartMate II Left Ventricular Assist Devices May Not Persist to One Year. <i>ASAIO Journal</i> , 2017 , 63, 401-407	3.6	10
54	Novel Left Heart Catheterization Ramp Protocol to Guide Hemodynamic Optimization in Patients Supported With Left Ventricular Assist Device Therapy. <i>Journal of the American Heart Association</i> , 2019 , 8, e010232	6	10
53	Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 550-7	2.6	10
52	A possible role for systemic hypoxia in the reactive component of pulmonary hypertension in heart failure. <i>Journal of Cardiac Failure</i> , 2013 , 19, 50-9	3.3	10
51	Treadmill testing improves survival prediction models in pulmonary arterial hypertension. <i>American Heart Journal</i> , 2011 , 162, 1011-7	4.9	10
50	Predictors and Clinical Outcomes of Vasoplegia in Patients Bridged to Heart Transplantation With Continuous-Flow Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2019 , 8, e013108	6.1	9
49	Hemodynamic ranges during daily activities and exercise testing in patients with pulmonary arterial hypertension. <i>Journal of Cardiac Failure</i> , 2014 , 20, 485-91	3.3	8
48	Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2011 , 30, 1153-60	5.8	8
47	The pharmacokinetics of racemic verapamil in patients with impaired renal function. <i>Journal of Clinical Pharmacology</i> , 1991 , 31, 45-53	2.9	8
46	Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension: Temporal Trends, Predictors, and Outcomes. <i>Chest</i> , 2020 , 158, 2568-2578	5.3	8
45	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 948-955	5.8	7
44	Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. <i>Respiratory Medicine Case Reports</i> , 2015 , 14, 13-5	1.2	7

43	EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	7
42	United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. <i>Chest</i> , 2021 , 159, 311-327	5.3	7
41	Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry.. <i>Journal of the American Heart Association</i> , 2022 , e024969	6	7
40	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease: Insights From the PVDOMICS Program. <i>Circulation: Heart Failure</i> , 2020 , 13, e006363	7.6	6
39	Features of cardiac allograft coronary endothelial dysfunction. <i>American Journal of Cardiology</i> , 2009 , 103, 1154-8	3	6
38	Thrombocytopenia independently predicts death in idiopathic PAH. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2019 , 48, 34-38	2.6	6
37	Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 1372-1380	5.8	6
36	Characterization of Prostacyclin-associated Leg Pain in Patients with Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 206-212	4.7	6
35	Integrated Use of Perfusion SPECT/CTA Fusion Imaging and Pulmonary Balloon Angioplasty for Chronic Pulmonary Thromboembolism. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 532-534	5	5
34	Early trends in N-terminal pro-brain natriuretic peptide values after left ventricular assist device implantation for chronic heart failure. <i>American Journal of Cardiology</i> , 2014 , 114, 1257-63	3	5
33	Hemodynamic monitoring in pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 173-8	3.8	5
32	Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894019845615	2.7	4
31	Outcomes After Noncardiac Surgery for Patients with Pulmonary Hypertension: A Historical Cohort Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020 , 34, 1506-1513	2.1	4
30	Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1331-1340	15.1	4
29	Impact of Right Ventricular Dysfunction on Short-term and Long-term Mortality in Sepsis: A Meta-analysis of 1,373 Patients. <i>Chest</i> , 2021 , 159, 2254-2263	5.3	4
28	Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894019880086	2.7	4
27	The usefulness of submaximal exercise gas exchange in pulmonary arterial hypertension: a case series. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2010 , 4, 35-40	3.4	3
26	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , 2021 , 11, 20458940211020913	2.7	3

25	Resolution of severe pulmonary arterial hypertension complicating adult-onset Still's disease. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 1140-4	5.8	3
24	Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR). <i>Annals of the American Thoracic Society</i> , 2020 ,	4.7	3
23	Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 761-764	10.2	3
22	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 1301-1326	5.8	3
21	REPLACE and the role of riociguat in pulmonary arterial hypertension therapy. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 546-547	35.1	2
20	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	2
19	Diagnostic dilemmas in pulmonary hypertension. <i>Heart Failure Clinics</i> , 2012 , 8, 331-52	3.3	1
18	The Usefulness of Submaximal Exercise Gas Exchange in Pulmonary Arterial Hypertension: A Case Series. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2010 , 4, 117954842020110	3.4	1
17	Response to Letter Regarding Article, Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial. <i>Circulation</i> , 2010 , 122,	16.7	1
16	Beta blockade in patients with congestive heart failure. Why, who, and how. <i>Postgraduate Medicine</i> , 2000 , 108, 103-6, 109-10, 116-8	3.7	1
15	Ambulatory Hemodynamic Monitoring in Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2008 , 7, 405-410	0.5	1
14	Topic-Based, Recent Literature Review on Pulmonary Hypertension. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 3109-3121	6.4	1
13	Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020923957	2.7	0
12	Transcatheter Nonductal Reverse Potts Shunt Creation in Pulmonary Arterial Hypertension.. <i>Circulation: Cardiovascular Interventions</i> , 2021 , CIRCINTERVENTIONS121011315	6	0
11	Mate-pair sequencing identifies a cryptic mutation in hereditary pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020933081	2.7	0
10	Recipient Selection and Management Before Cardiac Transplantation. <i>American Journal of the Medical Sciences</i> , 1997 , 314, 139-152	2.2	
9	Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence. <i>Future Cardiology</i> , 2008 , 4, 459-68	1.3	
8	The effects of sildenafil and acetazolamide on breathing efficiency during hypoxic exercise. <i>FASEB Journal</i> , 2008 , 22, 1173.13	0.9	

- 7 Pulmonary Hypertension in Chronic Heart and Lung Disease. *Respiratory Medicine*, **2015**, 93-113 0.2
- 6 The Future of Pulmonary Hypertension **2016**, 359-367
- 5 Positioning Newer Agents: Riociguat, Selexipag, and Oral Treprostinil in the Current Landscape. *Advances in Pulmonary Hypertension*, **2017**, 15, 193-197 0.5
- 4 Cardiac and Lung Transplantation **2014**, 291-303
- 3 PH Grand Rounds: Puzzling Etiology of Pulmonary Hypertension Resolved. *Advances in Pulmonary Hypertension*, **2014**, 13, 65-67 0.5
- 2 Cardiac and Lung Transplantation and the Right Heart **2021**, 317-329
- 1 Response. *Chest*, **2018**, 154, 1262-1264 5.3